Maple technical analysis: Support test at $0.1998 in focus
Maple (SYRUP) is trading at $0.2078, marking a daily decline of 7.19%. The token now sits below its key short- and medium-term moving averages but retains positioning above the long-term average.
Highlights
- SYRUP/USD trades below key short- and medium-term moving averages, indicating persistent downward pressure from sellers.
- Technical momentum indicators all indicate strong selling dominance and a lack of clear intraday trend strength.
- Next sessions are expected to see price confined between $0.1998 and $0.2158, with high probability of continued decline.
Momentum weakens as downside indicators align with oversold levels
SYRUP/USD trades below the MA-20 ($0.2154) and MA-50 ($0.2195), with price action still supported above the MA-200 at $0.1944. The Kijun level from Ichimoku is at $0.2166, acting as immediate resistance. Momentum indicators confirm prevailing downside: MACD and Awesome Oscillator are both on Sell, Bull/Bear Power indicates seller dominance, and ADX remains Neutral, signifying a lack of directional strength. RSI prints 31.856 (Sell), while both Stoch RSI and CCI show deeply oversold readings, reflecting a market stretched to the downside and closing near daily lows.
Downside risk prevails as key support faces renewed pressure
In the short term, SYRUP/USD is expected to consolidate within a volatility band of $0.1998 to $0.2158. The probability of a short-lived rebound is very low, with further downside seen as much more likely. If price breaks below support at $0.1998, additional losses may follow. Conversely, a move above resistance at $0.2166 would be needed to trigger any sustainable upside potential.
Earlier, analysts noted that Maple was experiencing persistent downside pressure amid ongoing bearish momentum according to key technical indicators. The latest price action confirms this prevailing weakness, emphasizing that traders should monitor the $0.1998 support as a critical level for assessing further downside risk in the near term.